Article
Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis.
Future oncology (London, England) - 1 May 2022
Haeussler Katrin, Wang Xuan, Winfree Katherine B, D'yachkova Yulia, Traore Sory, Puri Tarun, Thom Howard, Papagiannopoulos Christos, Nassim Maria, Taipale Kaisa
Abstract excerpt
Aim: To evaluate the comparative efficacy and safety of identified first-line therapies for patients with EGFR mutation-positive (EGFRm+) advanced non-small-cell lung cancer (NSCLC), with a focus on ramucirumab + erlotinib. Methods: In the absence of head-to-head studies, a Bayesian network meta-analysis was conducted using randomized clinical trial data to evaluate first-line systemic therapies with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.